On 6 September 2017, the website of the BeNeLuxA collaboration, beneluxa.org, was officially launched (see Belgian and Dutch government press releases). The BeNeLuxA collaboration is an initiative between Belgium, the Netherlands, Luxembourg and Austria on pharmaceutical policy that aims to ensure sustainable and affordable access to innovative medicines (in particular, orphan drugs) by levelling the playing field. It extends to joint horizon scanning, health technology assessment on innovation, pricing and reimbursement and information sharing.
The BeNeLuxA website provides a single point of contact for interested parties, such as pharmaceutical companies that would like to participate in joint negotiations or other countries that would like to join the initiative. It contains information on the nature of the collaboration and outcomes achieved, as well as relevant documentation, including for example, scientific reports commissioned by the BeneLuxA and policy documents.
A prior version of this post was originally published by the same authors in Practical Law – Life Sciences, September 2017 Issue (Thomson Reuters).